Confiden'al / Do Not Distribute - Esperovax
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
1 Confiden'al / Do Not Distribute
mRNA vaccines - “a new era in biologicals”
• Lipid Nanoparticles Achieve >90% efficacy
• Developed in 10 months
• Uses the body’s cells to produce protein
• Easily modified (Plug and Play)
2
But, significant challenges exist for mRNA technology
to be used broadly for other indica;ons…
Frozen storage is not viable in a
non-pandemic seBng
Injecting mRNA can lead to intense reactions
May not produce a strong mucosal
response and pa;ents are hesitant
3
Large Distribu-on of Vaccines is Difficult
Production
Purification
Quality Control
Cold Storage
• CoV-2 Herd immunity 70%
• 5.5 Billion People
• Moderna 2X, 11B syringes
Health Care Professional
Required for use
Confidential / Do Not Distribute 4
Egress RD ™
(Rapid Deployment)
Egress RD Advantage
The Esperovax oral
• Stable at room temperature
mRNA pla
Turning yeast cells into mini-vaccine factories
We’ve modified the cell wall of yeast cells to
mRNA
keep it intact but make it permeable Nanoparticles
Baker’s Egress RD
Standard Yeast Cell Yeast Cell
Cell Wall Permeable
Cell Wall
The cells are then encoded with the gene for a vaccine
anEgen, enabling the cells to conEnuously secrete mRNA
6
Egress RD vaccine elicit robust immunity
The yeast is then given orally via a
capsule or liquid which dissolves
a;er it passes the stomach
Once in the intestines, the
yeast continues to secrete
mRNA for up to ~12 hours
7
Esperovax overview
Esperovax overview
• Novel oral mRNA platform with 3 pending patents
• Novel oral mRNA platform with 3 pending patents
• Demonstrated immunogenicity in mouse
• Demonstrated immunogenicity in mouse
• Awarded 2020 BARDA contract
• Awarded 2020 BARDA contract
9
8
Major Competitors
How Esperovax Compares,
RNA (short lived) Other DNA
√ = Positive
Esperovax Moderna Astra Zeneca Vaxart
Oral Delivery Yes No No Yes
Rapid Development and Regulatory Path √√√ √√√ √ √√√
No Genotoxicity √√√ √√√ √√ √
No Inflammation √√√ √ √√ √√
Rapid Deployment √√√√ √√ √ √√
Confiden+al / Do Not Distribute 9
Our Leadership Team
David O’Hagan, PhD Savita Nikam PhD Roger Newton PhD, FAHA, FACN
Co-Founder, Co-Founder, Co-Founder,
Chief Executive Officer Chief Scientific Officer Board Chairman & Investor
Dave Peralta Eli Thomssen, BS, MBA
Executive Board Advisor Board Member 10Scien&fic Advisory Board
Randy Scheckman PhD Robin Robinson PhD, Kevin Gilligan PhD,
The Nobel Prize in Physiology or Medicine Former Director of the Biomedical Former HHS/BARDA and
2013, for the discovery of machinery regulating Advanced Research and Senior Medical Advisor for
vesicle traffic, a major transport system in cells Development Authority (BARDA) Pandemic Influenza
Adolfo García-Sastre PhD, Co-director of Jürgen A. Richt PhD KSU Regents
Global Health & Emerging Pathogens Institute Distinguished Professor & KBA
at The Icahn School of Medicine at Mount Sinai Eminent Scholar 11Business model --- 3 parallel paths
• CoV-2 Booster Market
Esperovax • RSV
Programs
• C. Diff • Animal health
• Norovirus • Other Indications
Pharma
• Influenza Grants
Partnerships
12Significant Egress RD pla2orm opportuni6es
Total value = $192B
US Biologicals Market
13Exit Strategy
Primary path: M&A exit to a major
vaccine company within 12-36 months
Egress RD provides a novel oral plaDorm
for infecFous disease, allergy & cancer
Selected acquirors shown to the right →
Parallel path: IPO following a successful
Phase 1 human study in a key disease
14Thank You!
David O’Hagan
Chief Execu9ve Officer
dohagan@esperovax.com
248.667.1845
15Egress RDTM In-Vitro VLP Production and Analysis
Enveloped VLPs (EVLP)
EVLP
Budding
From Yeast
GFP VLPs by FLOW
TEM
mRNA VLPs (RVLP) CoV-2 S-protein RVLPs
RVLP
Budding
From Yeast
Transfection
of GFP-RVLPs
Translation in
DC 2.4 cellsVLPs in-Vivo Expression in Mouse
GAG-GFP VLPs enter Enterocytes and
payers patch cells
Optimal
Dose
2.5x106 In
Mice
)
ells lls
)
5 c ce 5 )
Enterocytes on the 0 5 0 5 )
X1 10 X1 0
surface of microvilli .5 5X 25 X1
(2 .2 (1
. .5
(1 (2You can also read
